Aspirin attenuates the incidence of silent brain lesions in patients with nonvalvular atrial fibrillation

Circulation Journal

Volumn 68, Issue 5, 2004, Pages 410-416

  Sato, Hiroshi ^a   Koretsune, Yukihiro ^b   Fukunami, Masatake ^c   Kodama, Kazuhisa ^d   Yamada, Yoshio ^e   Fujii, Kenshi ^f   Kitagawa, Kazuo ^a   Hori, Masatsugu ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA NATIONAL HOSPITAL   (Japan)

^c OSAKA GENERAL MEDICAL CENTER   (Japan)

^d OSAKA POLICE HOSPITAL   (Japan)

^e OSAKA ROSAI HOSPITAL   (Japan)

^f Sakurabashi Watanabe Hospital   (Japan)

Author keywords

Aspirin; Atrial fibrillation; Cerebral infarction; Magnetic resonance imaging

Indexed keywords

ACETYLSALICYLIC ACID;

ADULT; AGED; ARTICLE; BASAL GANGLION; BRAIN INFARCTION; CEREBROVASCULAR DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOPPLER ECHOCARDIOGRAPHY; FEMALE; HEART ATRIUM ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART VALVE REGURGITATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; RISK FACTOR; SINUS RHYTHM; STROKE; WHITE MATTER;

AGED; ASPIRIN; ATRIAL FIBRILLATION; BRAIN; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; FEMALE; HUMANS; INCIDENCE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PREVALENCE; RISK FACTORS;

EID: 2442695038     PISSN: 13469843     EISSN: None     Source Type: Journal    
DOI: 10.1253/circj.68.410     Document Type: Article

References (43)

1. Kobayasi S, Okada K, Koide H, Bokua H, Yamaguti S. Subcortical silent brain infarction as a risk factor for clinical stroke. Stroke 1997; 28: 1932-1939.
2. Price TR, Manolio TA, Konmal RA, Kittner SJ, Yue NC, Robbins J, et al. Silent brain infarction on magnetic resonance imaging and neurological abnormalities in communitiy-dwelling older adults: The Cardiovascular Health Study. Stroke 1997; 28: 1158-1164.
3. Uehara T, Tabuchi M, Mori E. Risk factors for silent cerebral infarsts in subcortical white matter and basal ganglia. Stroke 1999; 30: 378-382.
4. Lee S, Park S, Ki H, Gwon H, Chung C, Byun HH, et al. Prevalence and risk factors of silent cerebral infarction in apparently normal adults. Hypertension 2000; 36: 73-77.
5. Adachi T, Kobayashi S, Yamaguchi S, Okada K. MRI findings of small subcortical 'lacunar-like' infarction resulting from large vessel disease. J Neurol 2000; 247: 280-285.
6. Davis P, Clarke W, Bendixen B, Adams HJ, Woolson R, Culebras A. Silent cerebral infarction in patients enrolled in the TOAST study. Neurology 1996; 46: 942-948.
7. Chodosh E, Foulkes M, Kase C, Wolf P, Mohr J, Hier D, et al. Silent stroke in the NINCDS Stroke Data Bank. Neurology 1988; 38: 1674-1679.
8. Kase C, Wolf P, Chodosh E, Zacker H, Kelly Hayes M, Kannel W, et al. Prevalence of silent stroke in patients presenting with initial stroke: The Framingham Study. Stroke 1989; 20: 850-852.
9. Ricci S, Celani M, La Rosa F, Righetti E, Duca E, Caputo N. Silent brain infarctions in patients with first-ever stroke: A community-based study in Umbria, Italy. Stroke 1993; 24: 647-651.
10. Feinberg WM, Seeger JF, Carmody RF, Anderson DC, Hart RG, Pearc LA. Epidemiologic features of asymptomatic cerebral infarction in patients with nonvalvular atrial fibrillation. Arch Intern Med 1990; 150: 2340-2344.
11. Ezekowitz MD, James KE, Nazarian SM, Davenport J, Broderick JP, Gupta SR, et al. Silent cerebral infarction in patients with nonrheumatic atrial fibrillation. Circulation 1995; 92: 2178-2182.
12. Fujiwara T, Yamawaki S, Touhouda Y. Incidence of silent cerebral infarction in patients with major depression. Stroke 1993; 24: 1631-1634.
13. Okada Y, Sadoshima S, So Y, Ishizuka T, Fujishima M. Asymptomatic cerebrovascular lesions in hypertensive cerebral hemorrhage. Jpn J Stroke 1992; 14: 187-191.
14. Yamashita T, Ogawa S, Aizawa Y, Atarashi H, Inoue H, Ohe T, et al. Investigation of the optimal treatment strategy for atrial fibrillation in Japan. Circ J 2003; 67: 738-741.
15. Narumiya T, Sakamaki T, Sato Y, Kanmatsuse K. Relationship between left atrial appendage function and left atrial thrombus in patients with nonvalvular chronic atrial fibrillation and atrial flutter. Circ J 2003; 67: 68-72.
16. Kumral E, Balkir K, Uzuner N, Evyapan D, Nalbantgil S. Microembolic signal detection in patients with symptomatic and asymptomatic lone atrial fibrillation. Cerebrovasc Dis 2001; 12: 192-196.
17. Petersen P, Boysen G, Godtfredsen J, Andersen E, Andersen B. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: The Copenhagen AFASAK study. Lancet 1989; 1: 175-179.
18. SPAF 1. The Stroke Prevention in Atrial Fibrillation Study: Final results. Circulation 1991; 84: 527-539.
19. SPAF Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994; 343: 687-691.
20. SPAF Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: The Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348: 633-638.
21. SPAF Investigators. Patients with nonvalvular atrial fibrillation at low-risk of stroke during treatment with aspirin: The Stroke Prevention in Atrial Fibrillation III Study. JAMA 1998; 279: 1273-1277.
22. Braffman B, Zimmerman R, Trojanowski J, Gonatas N, Hickey W, Schlaepfer W. Brain MR: Pathologic correration with gross and histopathology. 1. Lacunar infarction and Virchow-Robin spaces. Am J Neuroradiol 1988; 9: 621-628.
23. Jorgensen HS, Nakayama H, Raaschou HO, Gam J, Olsen TS. Silent infarction in acute stroke patients: Prevalence, localization, risk factors, and clinical significance: The Copenhagen Stroke Study. Stroke 1994; 25: 97-104.
24. Shimada K, Kawamoto A, Matsubayashi K, Ozawa T. Silent cerebrovascular disease in the elderly: Correlation with ambulatory pressure. Hypertension 1990; 16: 692-699.
25. Howard G, Wagenknecht LE, Cai J, Cooper L, Kraut MA, Toole JF. Cigarette smoking and other risk factors for silent cerebral infarction in the general population. Stroke 1998; 29: 913-917.
26. Longstreth WT Jr, Bernick C, Manolio TA, Bryan N, Jungreis CA, Price TR. Lacunar infarcts defined by magnetic resonance imaging of 3660 elderly people: The Cardiovascular Health Study. Arch Neurol 1998; 55: 1217-1225.
27. Hougaku H, Matsumoto M, Handa N, Maeda H, Itoh T, Tsukamoto Y, et al. Asymptomatic carotid lesions and silent cerebral infarction. Stroke 1994; 25: 566-570.
28. Lindgren A, Roijer A, Rudling O, Norrving B, Larsson E, Eskilsson J, et al. Cerebral lesions on magnetic resonance imaging, heart disease, vascular risk factors in subjects without stroke: A population-based study. Stroke 1994; 25: 929-934.
29. Schuier F, Vise W, Hossmann K, Zulch K. Cerebral microembolization. II. Morphological studies. Arch Neurol 1978; 35: 264-270.
30. de Leeuw F-E, deGroot J, Oudkerk M, Witteman J, Hofman A, Gijn J, et al. Aortic atherosclerosis at middle age predicts cerebral white matter lesions in the elderly. Stroke 2000; 31: 425-429.
31. de Leeuw F-E, deGroot J, Oudkerk M, Kors J, Hofman A, Gijn J, et al. Atrial fibrillation and the risk of cerebral white matter lesions. Neurology 2000; 54: 1795-1800.
32. Minamino T, Kitakaze M, Sato H, Asanuma H, Funaya H, Koretsune Y, et al. Plasma levels of nitrite/nitrate and platelet cGMP levels are decreased in patients with atrial fibrillation. Arterioscler Thromb Vasc Biol 1997; 17: 3191-3195.
33. Minamino T, Kitakaze M, Sanada S, Asanuma H, Kurotobi T, Koretsune Y, et al. Increased expression of P-selectin on platelets is a risk factor for silent cerebral infarction in patients with atrial fibrillation: Role of nitric oxide. Circulation 1998; 98: 1721-1727.
34. Noris M, Morigi M, Donadelli R, Aiell S, Foppolo M, Todechini M, et al. Nitric oxide synthesis by cultured endothelial cell is modulated by flow condition. Circ Res 1995; 76: 536-543.
35. Topper J, Cai J, Falb D, Gimborne M. Identification of vascular endothelial genes differentially responsive to fluid mechnical stimuli: Cycloxygenase, manganese superdismutase, and endothelial cell nitric oxide synthetase are selectively up-regulated by steady laminar sheaar stress. Proc Natl Acad Sci USA 1996; 93: 10417-10422.
36. Ylikoski A, Erkinjuntti T, Raininko R, Sarna S, Sulkava R, Tilvis R. White matter hyperintensities on MRI in the neurologically non-diseased elderly: Analysis of cohorts of consecutive subjects aged 55-85 years living at home. Stroke 1995; 26: 1171-1177.
37. Longstreth W, Manoli T, Arnold A, Burke G, Bryan N, Jungreis C, et al. Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people: The cardiovascular health study. Stroke 1996; 27: 1274-1282.
38. Hart RG, Pearce LA, Miller VT, Anderson DC, Rothrock JF, Albers GW, et al. Cardioembolic versus non-cardioembolic strokes in atrial fibrillation: Frequency and effect of antithrombotic agents in the Stroke Prevention in Atrial Fibrillation Studies. Cerebrovasc Dis 2000; 10: 39-43.
39. Petersen P. Thromboembolic complications in atrial fibrillation. Stroke 1990; 21: 4-13.
40. Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, Halperin JL. Stroke with intermittent atrial fibrillation: Incidence and predictors during aspirin therapy. J Am Coll Cardiol 2000; 35: 183-187.
41. Corbalan R, Arriagada D, Braun S, Tapia J, Huete I, Kramer A, et al. Risk factors for systemic embolism in patients with paroximal atrial fibrillation. Am Heart J 1992; 124: 149-153.
42. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-reumatic atrial fibrillation after transient ischemic attack or minor stroke. Lancet 1993; 342: 1255-1262.
43. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-1457.